Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.51 |
| ▸ | HTR2B | P41595 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648070 | 0.91 | SMN1; SMN2 (0.44) | HTR2CHTR2BEIF2AK3HTR2ALMNA | |
| SCHEMBL6649245 | 0.91 | HTR2C (0.46) | HTR2CHTR2BEIF2AK3HTR2ALMNA | |
| SCHEMBL6643731 | 0.86 | HTR2C (0.51) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6805188 | 0.85 | HTR2C (0.51) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6644163 | 0.84 | MEN1 (0.54) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6798695 | 0.84 | HTR2C (0.49) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6645958 | 0.84 | EIF2AK3 (0.43) | HTR2CHTR2BEIF2AK3HTR2ALMNA | |
| SCHEMBL6646057 | 0.84 | HTR2C (0.50) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6643695 | 0.84 | HTR2C (0.50) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A | |
| SCHEMBL6644622 | 0.83 | MEN1 (0.48) | HTR2CHTR2BALDH1A1EIF2AK3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | HTR2C 1349/4885HTR2B 485/4885ALDH1A1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.